Do your simvastatin patients need more help reaching their LDL-C goals?

LIPITOR tablets provide LDL-C reductions of 39% to 60% across the full dose range1

LIPITOR tablets are contraindicated in patients with a known hypersensitivity to any component of this product, in patients with active liver disease or unexplained persistent elevations of hepatic transaminases, in women who are or may become pregnant or who are breastfeeding.

Lipitor. Proven to help lower LDL-C, backed by OVER 20 years of experience1
 

As seen in CURVES, LIPITOR showed significantly greater LDL-C reductions than simvastatin across a range of doses.2

Efficacy chart

The FDA recommends that patients who do not meet their LDL-C goal on simvastatin 40 mg be placed on alternative LDL-C-lowering treatments.3,4,5,6

Study Background

CURVES (N=534) was an 8-week, randomized, open-label, parallel-group study that compared milligram-equivalent doses of LIPITOR® (atorvastatin calcium) tablets with simvastatin, pravastatin, lovastatin, and fluvastatin in patients with LDL-C ≥160 mg/dL and TG ≤400 mg/dL. Baseline LDL-C values were similar and patient demographics evenly distributed across treatment groups. Patients were randomized to LIPITOR 10 mg (n=73), 20 mg (n=51), 40 mg (n=61), or 80 mg (n=10); simvastatin 10 mg (n=70), 20 mg (n=49), or 40 mg (n=61); pravastatin 10 mg (n=14), 20 mg (n=41), or 40 mg (n=25); or lovastatin 20 mg (n=16), 40 mg (n=16), or 80 mg (n=11).

LIPITOR 10 mg, 20 mg, and 40 mg produced greater reductions in LDL-C (38%, 46%, and 51%, respectively; P≤.01) compared with equivalent doses of simvastatin, pravastatin, lovastatin, and fluvastatin. LIPITOR 10 mg produced LDL-C reductions comparable with or greater than simvastatin 10 mg, 20 mg, and 40 mg (28%, 35%, and 41%, respectively); pravastatin 10 mg, 20 mg, and 40 mg (19%, 24%, and 34%, respectively); lovastatin 20 mg and 40 mg (29% and 31%, respectively); and fluvastatin 20 mg and 40 mg (17% and 23%, respectively).2

References

  1. LIPITOR Product Document [all data referenced to the LPD have to be: a) reviewed and adapted according to the country-specific regulation; b) referenced with and in accordance to the local LIPITOR prescribing information].
  2. Jones P, Kafonek S, Laurora I, Hunninghake D; for CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81(5):582-587.
  3. US Food and Drug Administration website. FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Updated February 2, 2012. Accessed October 26, 2015. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor. June 8, 2011. Accessed November 10, 2020.
  4. US Food and Drug Administration website. FDA Drug Safety Communication: Revised dose limitation for Zocor (simvastatin) when taken with amiodarone. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor. December 15, 2011. Accessed November 10, 2020.
  5. US Food and Drug Administration website. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs. February 28, 2012. Accessed November 10, 2020.

  6. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625.